Cancer Australia has updated its ‘Guidance for the management of early breast cancer’ to include scalp cooling in connection with chemotherapy to reduce the risk of hair loss for patients receiving chemotherapy treatment.

The adoption of this recommendation by Cancer Australia follows the US National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in oncology for breast cancer (Version 1.2019) update in 2019 to include scalp cooling as a Category 2A recommendation. The Australian guidance also notes that scalp cooling may be less effective with anthracycline-containing regimens.

“The inclusion of scalp cooling in the Australian Guidance is an important step towards the treatment becoming a standard of care in many parts of the world. We hope that this will further pave the way for the adoption of scalp cooling in international guidelines,” says PAXMAN’s CEO Richard Paxman.

To date, PAXMAN has over 160 scalp cooling systems installed in Australia in 91 locations.

“It is fitting that the new guidelines have a focus on supportive care as well as treatment advances,” says Prof. Fran Boyle, Medical Oncologist at the Mater Hospital Sydney, and Chair of the Guidance Steering Committee. “We know that for many women, the threat of hair loss impedes the delivery of evidence-based chemotherapy, and that scalp cooling can make a real difference to their experiences.”

About Cancer Australia
Cancer Australia was established by the Australian Government in 2006 to benefit all Australians affected by cancer, and their families and carers. Cancer Australia aims to reduce the impact of cancer, address disparities and improve outcomes for people affected by cancer by leading and coordinating national, evidence-based interventions across the continuum of care. Cancer Australia works collaboratively and liaises with a wide range of groups, including those affected by cancer, key stakeholders and service providers with an interest in cancer control. The agency also focuses on populations who experience poorer health outcomes, including Aboriginal and Torres Strait Islander peoples and people living in rural and remote Australia. As the lead national cancer control agency, Cancer Australia also makes recommendations to the Australian Government about cancer policy and priorities.

Contacts

Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,500 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company’s Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.

Attachments

PAXMAN announces that Cancer Australia’s Guidance for the management of early breast cancer now recommends scalp cooling